Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Mitsubishi, J&J to End Stelara Co-Promotion in Japan at Year-End
Mitsubishi Tanabe Pharma said on September 16 that it will wind up co-promotion activities for Janssen Pharmaceutical’s (J&J) anti-IL-12/23p40 antibody Stelara (ustekinumab) in Japan at the end of December, when their partnership deal is set to expire. Mitsubishi Tanabe will…
To read the full story
Related Article
- Janssen, Mitsubishi Tanabe Expand Copromotion Deal for Stelara
February 6, 2020
- Mitsubishi Tanabe, Janssen Revise Copromotion Framework for Stelara
June 29, 2018
- Janssen, Mitsubishi Tanabe to Copromote Stelara for Crohn’s Disease
February 6, 2017
BUSINESS
- Nippon Shinyaku to Take Over UCB’s Fintepla in Japan from April
February 25, 2026
- Opdivo-Yervoy Expands Label for Colorectal Cancer in South Korea
February 25, 2026
- Daiichi Sankyo Taps Ex-Novartis CMO John Tsai as R&D Head
February 24, 2026
- Shionogi to Absorb Torii in April 2027
February 24, 2026
- Sumitomo, Partners Launch Malaria Vaccine Project Targeting Mid-2030s Approval
February 24, 2026
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Following Hisamitsu Pharmaceutical’s decision to go private through a roughly 400 billion yen management buyout (MBO), industry observers are weighing…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…